LB-54640 is under clinical development by LG Chem and currently in Phase I for Obesity. According to GlobalData, Phase I drugs for Obesity have a 59% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how LB-54640’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Smarter leaders trust GlobalData
LB-54640 overview
LB-54640 is under development for the treatment of genetic obesity. It is administered by the oral route. It acts by targeting MC4R.
LG Chem overview
LG Chem, a subsidiary of LG Corp, is a chemical manufacturer. The company manufactures and markets petrochemicals, IT and electronic materials, and energy solutions. Its product portfolio comprises polyvinyl chloride (PVC), ethylene, propylene, butadiene, benzene, polarizer, glass substrate, semiconductor materials and RO membranes, among others. It also offers growth hormone, vaccine, anti-diabetic products, and manufactures and supplies display and battery materials for LCD photoresist, OLED materials, battery materials and others. It owns and operates manufacturing facilities in Daesan, Yeosu, Ochang, Cheongju, Ulsan, Naju, Iksan, Paju and Gimcheon. The company has operations in China, India, Germany, the US, Vietnam, Brazil, Taiwan, Hong Kong and Poland, among others. LG Chem is headquartered in Seoul, South Korea.
For a complete picture of LB-54640’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
